About Us
Author Guidelines
Contact Us
Supplier Info
 


Current Issue
Sample issue of JATCurrent Issue


Contact Info:
6600 W. Touhy Ave.
Niles, IL 60714
Tel: 847.647.2900
Fax: 847.647.1155
circulation@jatox.com

 

 
   

Journal of Analytical Toxicology Article Abstracts

Journal of Analytical Toxicology Horizontal Line

Published: Journal of Analytical Toxicology, ISSN 0146-4760, Volume 27, Number 2, March 2003, pp. 103-105

Enzyme Immunoassay Validation for the Detection of Buprenorphine in Urine
V. Cirimele*, P. Kintz, S. Lohner, and B. Ludes
Institut de Médecine Légale, Laboratoire de Toxicologie, 11, rue Humann, 67085 Strasbourg, France

A solid-phase enzyme immunoassay involving microtiter plates was proposed by Microgenics to screen buprenorphine in urine. The intra-assay precision at 10 ng/mL was 7.7% (coefficient of variation). The immunoassay was determined to have no cross-reactivity with codeine, dihydrocodeine, morphine, ethylmorphine, 6-monoacetylmorphine, methadone, pholcodine, propoxyphene, dextromoramide, and dextromethorphan at 1 and 10 mg/L. A low cross-reactivity (3% at 1 ng/mL) was observed at low concentrations of norbuprenorphine. After comparing this new immunological test (Singlestep™ ELISA) for 76 urine specimens with our validated high-performance liquid chromatography–electrospray mass spectrometry (HPLC–ES-MS) procedure, an optimum cutoff concentration of 2 ng/mL was determined for the kit. At this cutoff, the screening assay was able to determine more than 90% of true results with 43.4% true positives and 48.7% true negatives. Four positive urines (5.3%) were not confirmed by HPLC–ES-MS. In only one case, the negative urine test was confirmed as positive by HPLC–ES-MS (buprenorphine: 62.5 ng/mL). Buprenorphine concentrations determined by HPLC–ES-MS ranged from 1.2 to 1052 ng/mL. Of the four potential adulterants (hypochloride 50 mL/L, sodium nitrite 50 g/L, liquid soap 50 mL/L, and sodium chloride 50 g/L) that might be added to a positive urine specimen, none were able to cause a false-negative response by the immunoassay. The results of this study support the concept that the Singlestep ELISA for buprenorphine determination in urine should be considered as a new, valided screening procedure.

Reproduction of editorial content of this journal is prohibited without publisher’s permission.

This article is available in its entirety by fax for $40.00 each.
Visa, MasterCard and AMEX accepted.

To order electronically click here
or call: 847-647-2900 ext. 1323
or fax request to: 847-647-1155.

To order multiple copies click here.

Please indicate JAT volume and issue along with page numbers.


| Home | Subscribe | Current Issue | Back Issues | Search | Advertise | Other Publications |